Dr. Beauregard is an assistant professor in the Department of Radiology and Nuclear Medicine at Laval University, a clinician scientist in the Oncology axis of the CHU Research Centre of Quebec – Laval University, and a specialist in nuclear medicine in the Department of Medical Imaging of the CHU of Quebec. Dr. Jean-Mathieu Beauregard completed his residency in nuclear medicine and his master’s degree in radiobiology at the Université de Sherbrooke. He completed additional training at the Peter MacCallum Cancer Centre in Melbourne, Australia from 2007 to 2010, during which he developed a strong interest in molecular imaging and radionuclide therapy for neuroendocrine tumors. Since his return to the CHU of Quebec, he has set up a new radiopeptide therapy program for neuroendocrine tumors. His research program is multidisciplinary and integrates translational research projects in medical and clinical physics.
Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.
At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.
In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.
Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.
9, rue McMahon
Canada G1R 3S3
- Adant, SamuelMaster studentCHUL+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
2705, boulevard Laurier
Canada G1V 4G2
- Bélanger, ValérieEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension firstname.lastname@example.org
11, côte du Palais
Canada G1R 2J6
- Bouvet, GuillaumeEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension email@example.com
6, rue McMahon
Canada G1R 2J6
- Desy, AlessandroDoctoral student+1 418-525-4444, extension firstname.lastname@example.org
- Lafrenière, NancyEmployeenancy.email@example.com@crchudequebec.ulaval.ca
- Shah, RashmiEmployeeCHUL+1 418-525-4444, extension 48230+1 418-525-4444, extension 48384+1 firstname.lastname@example.org
2705, boulevard Laurier
Canada G1V 4G2
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.Journal Article
Eur Urol Focus, 5 (6), pp. 998-1006, 2019.
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.Journal Article
Eur J Nucl Med Mol Imaging, 2019, ISSN: 1619-7070.
Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study.Journal Article
Phys Med Biol, 64 (17), pp. 175006, 2019, ISSN: 0031-9155.
Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations.Journal Article
Phys Med Biol, 64 (17), pp. 175004, 2019, ISSN: 0031-9155.
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.Journal Article
Eur J Nucl Med Mol Imaging, 46 (3), pp. 728-742, 2019, ISSN: 1619-7070.
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.Journal Article
Oper Neurosurg (Hagerstown), 15 (6), pp. 100-109, 2018.
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.Journal Article
EJNMMI Phys, 5 (1), pp. 25, 2018, ISSN: 2197-7364.
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.Journal Article
Oncotarget, 9 (37), pp. 24693-24706, 2018, ISSN: 1949-2553.
Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes.Journal Article
EJNMMI Phys, 5 (1), pp. 8, 2018, ISSN: 2197-7364.
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.Journal Article
Curr Opin Support Palliat Care, 12 (3), pp. 359-365, 2018, ISSN: 1751-4258.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
- National Program on Radioligand Therapy for Prostate Cancer, Subvention, Cancer de la prostate Canada, from 2018-01-01 to 2022-12-31
- Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-04-01 to 2021-03-31
- Therapie radiopeptidique personnalisee des patients atteints de tumeurs neuroendocrines, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2018-07-01 to 2020-06-30
- Upregulating expression of SSTR to enhance PRRT of neuroendocrine tumors, Subvention, L'Institut de recherche de la Société canadienne du cancer, Subventions pour l'innovation, from 2017-02-01 to 2020-01-31
Recently finished projects
- Acquisition of a pre-clinical positron emission tomography (PET) camera and a radiosynthesis unit, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2014-09-01 to 2018-12-31
- PARP-inhibitor radiosensitization in 177Lu-octreotate PRRT of neuroendocrine tumors, Subvention, Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, from 2016-07-01 to 2018-06-30
- Personalizing Radionuclide Therapy of Neuroendocrine Tumours., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Concours transitoire de subvention de fonctionnement : 2014-2015, from 2015-07-01 to 2019-06-30